Arcus Biosciences, Inc. (RCUS) Ownership
RCUS ownership summary
as of October 17, 2026- Institutions
- 74.9% of shares outstanding
- Insiders
- 28.80% of shares outstanding
- Shares outstanding
- 127.3M
- Float
- 90.5M shares available to trade
- Short interest
- 16.81% 13.1M shares short
- Days to cover
- 7.66 short interest up 0.3% vs prior month
- Institutions 74.91%
- Insiders 28.80%
RCUS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 12.89% | 16.4M | $363.1M | +1.2M (+7.8%) | June 30, 2026 |
| 2 | State Street Corp | 4.74% | 6.0M | $133.4M | +616,583 (+11.4%) | June 30, 2026 |
| 3 | Wellington Management Company LLP | 4.63% | 5.9M | $130.4M | −194,068 (−3.2%) | June 30, 2026 |
| 4 | Suvretta Capital Management, LLC | 3.75% | 4.8M | $105.7M | −254,570 (−5.1%) | June 30, 2026 |
| 5 | Vanguard Portfolio Management, LLC | 3.51% | 4.5M | $99.0M | +203,472 (+4.8%) | June 30, 2026 |
| 6 | FMR Inc | 3.18% | 4.0M | $89.6M | +2.9M (+247.5%) | June 30, 2026 |
| 7 | Vanguard Capital Management, LLC | 3.05% | 3.9M | $86.0M | +31,621 (+0.8%) | June 30, 2026 |
| 8 | Citadel Advisors Llc | 2.46% | 3.1M | $69.3M | +1.8M (+135.7%) | June 30, 2026 |
| 9 | Woodline Partners LP | 2.36% | 3.0M | $66.5M | −770,000 (−20.4%) | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 1.92% | 2.4M | $54.2M | +196,382 (+8.7%) | June 30, 2026 |
| 11 | Siren, L.L.C. | 1.90% | 2.4M | $53.5M | −586,647 (−19.5%) | June 30, 2026 |
| 12 | Fisher Asset Management, LLC | 1.68% | 2.1M | $47.3M | −51,008 (−2.3%) | June 30, 2026 |
| 13 | Marshall Wace Asset Management Ltd | 1.53% | 1.9M | $43.0M | −1.8M (−48.3%) | June 30, 2026 |
| 14 | Samlyn Capital, LLC | 1.22% | 1.5M | $34.2M | −361,230 (−18.9%) | June 30, 2026 |
| 15 | Dimensional Fund Advisors, Inc. | 1.13% | 1.4M | $31.7M | +8,097 (+0.6%) | June 30, 2026 |
| 16 | BNP Paribas Investment Partners SA | 1.11% | 1.4M | $31.4M | −235,221 (−14.2%) | June 30, 2026 |
| 17 | The Goldman Sachs Group Inc | 1.09% | 1.4M | $30.7M | +387,780 (+38.8%) | June 30, 2026 |
| 18 | Soleus Capital Management, L.P. | 0.92% | 1.2M | $25.9M | +716,755 (+158.6%) | June 30, 2026 |
| 19 | Sofinnova Ventures | 0.74% | 946K | $20.9M | +22,604 (+2.4%) | June 30, 2026 |
| 20 | Charles Schwab Investment Management Inc | 0.74% | 942K | $20.8M | +38,118 (+4.2%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 8.1M shares and 8 cut 4.3M.
RCUS top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | iShares Core S&P Small-Cap ETF | 4.23% | 5.4M | $119.0M | +1,287 (+0.0%) | September 30, 2026 |
| 2 | Vanguard Health Care Inv | 2.71% | 3.4M | $76.2M | −679,032 (−16.5%) | June 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 2.20% | 2.8M | $62.1M | −4,880 (−0.2%) | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 1.83% | 2.3M | $51.4M | −26,816 (−1.1%) | September 30, 2026 |
| 5 | State Street® SPDR® S&P® Biotech ETF | 1.64% | 2.1M | $46.1M | −39,850 (−1.9%) | September 30, 2026 |
| 6 | Vanguard Small Cap Index | 0.79% | 1.0M | $22.4M | +3 (+0.0%) | August 31, 2026 |
| 7 | Fidelity Small Cap Index | 0.77% | 978K | $21.6M | +8,361 (+0.9%) | July 31, 2026 |
| 8 | Invesco S&P SmallCap Momentum ETF | 0.68% | 865K | $19.1M | — | September 30, 2026 |
| 9 | Fidelity Select Biotechnology | 0.67% | 853K | $18.9M | — | August 31, 2026 |
| 10 | BNP Paribas US Small Cap ClassicC | 0.66% | 844K | $18.7M | −1,616 (−0.2%) | August 31, 2026 |
| 11 | State Street SPDR Port S&P 600 Sm CpETF | 0.65% | 828K | $18.3M | — | September 30, 2026 |
| 12 | Fidelity Small Cap Growth | 0.64% | 809K | $17.9M | — | July 31, 2026 |
| 13 | Belfius Equities Cure C Cap | 0.62% | 791K | $17.5M | — | March 31, 2026 |
| 14 | BGF World Healthscience A2 | 0.57% | 729K | $16.1M | — | June 30, 2026 |
| 15 | iShares Biotechnology ETF | 0.52% | 663K | $14.7M | −5,024 (−0.8%) | September 30, 2026 |
| 16 | iShares Russell 2000 Growth ETF | 0.52% | 658K | $14.5M | −833 (−0.1%) | September 30, 2026 |
| 17 | Vanguard MStar Small Cap Growth Indx Inv | 0.46% | 580K | $12.8M | −4,865 (−0.8%) | August 31, 2026 |
| 18 | BlackRock Health Sciences Opps Inv A | 0.45% | 572K | $12.7M | — | August 31, 2026 |
| 19 | iShares S&P Small-Cap 600 Growth ETF | 0.41% | 528K | $11.7M | — | September 30, 2026 |
| 20 | Vanguard Russell 2000 ETF | 0.40% | 514K | $11.4M | +12,212 (+2.4%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
RCUS insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-05 | Juan C Jaen | Sell | $21.41 | 31,823 | $681,330 |
| 2025-12-31 | Robert C Goeltz II | Sell | $23.38 | 6,552 | $153,186 |
| 2025-12-18 | Alexander Azoy | Sell | $22.25 | 4,343 | $96,632 |
| 2025-12-17 | Alexander Azoy | Sell | $22.16 | 2,113 | $46,824 |
| 2025-12-17 | Carolyn C Tang | Sell | $22.16 | 6,810 | $150,910 |
| 2025-12-17 | Jennifer Jarrett | Sell | $22.16 | 9,983 | $221,223 |
| 2025-12-17 | Juan C Jaen | Sell | $22.16 | 9,983 | $221,223 |
| 2025-12-17 | Richard Markus | Sell | $22.16 | 4,494 | $99,587 |
| 2025-12-17 | Robert C Goeltz II | Sell | $22.16 | 5,960 | $132,074 |
| 2025-12-17 | Terry J Rosen | Sell | $22.16 | 25,744 | $570,487 |
| 2025-12-16 | Richard Markus | Sell | $21.88 | 5,052 | $110,538 |
| 2025-12-16 | Terry J Rosen | Sell | $21.88 | 28,947 | $633,360 |
| 2025-12-16 | Robert C Goeltz II | Sell | $21.88 | 6,702 | $146,640 |
| 2025-12-16 | Juan C Jaen | Sell | $21.88 | 11,225 | $245,603 |
| 2025-12-16 | Jennifer Jarrett | Sell | $21.88 | 11,225 | $245,603 |
| 2025-12-16 | Carolyn C Tang | Sell | $21.88 | 7,658 | $167,557 |
| 2025-12-16 | Alexander Azoy | Sell | $21.88 | 2,376 | $51,987 |
| 2025-12-04 | Juan C Jaen | Sell | $24.71 | 82,997 | $2.1M |
| 2025-11-26 | Alexander Azoy | Sell | $26.00 | 1,900 | $49,400 |
| 2025-11-18 | Juan C Jaen | Sell | $19.75 | 5,050 | $99,738 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
RCUS shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns RCUS
Institutional investors own 74.9% of Arcus Biosciences's shares and insiders 28.80%. The largest holder is BlackRock Inc with 12.89% of the shares (16.4M), as of June 30, 2026. Among the top 20 institutions, 12 added shares and 8 reduced their stake in the latest filings. Short interest is 16.81% of the float, or 7.66 days of average trading volume. The share count rose 10,640.0% since 2016.
Related: RCUS analyst forecast, RCUS key metrics. See the RCUS stock overview for the latest quote and news.
RCUS ownership FAQ
Who owns the most Arcus Biosciences stock?
The largest shareholders of Arcus Biosciences are BlackRock Inc (12.89%), State Street Corp (4.74%), Wellington Management Company LLP (4.63%), Suvretta Capital Management, LLC (3.75%), Vanguard Portfolio Management, LLC (3.51%).
What percentage of Arcus Biosciences is owned by institutions?
Institutions hold 74.9% of Arcus Biosciences's shares outstanding; insiders hold 28.80%.
Which funds own Arcus Biosciences?
The largest fund holders of Arcus Biosciences are iShares Core S&P Small-Cap ETF (4.23%), Vanguard Health Care Inv (2.71%), Vanguard MStar Total Stk Mkt Idx Invest (2.20%), iShares Russell 2000 ETF (1.83%), State Street® SPDR® S&P® Biotech ETF (1.64%).
What is Arcus Biosciences's short interest?
13.1M shares of Arcus Biosciences were sold short, 16.81% of the float; at the average daily volume it would take 7.66 days to cover.
Are insiders buying or selling Arcus Biosciences?
Of the latest 20 reported insider transactions in Arcus Biosciences (since November 18, 2025), 0 were purchases and 20 were sales.
How many shares of Arcus Biosciences are outstanding?
Arcus Biosciences has 127.3M shares outstanding, of which 90.5M are in the public float.